Author: Ravi Shankar

News Summary

• Nutanix and Netris have announced a strategic collaboration to deliver a jointly engineered multitenant infrastructure stack designed specifically for neoclouds and enterprises — combining Nutanix Cloud Platform and its proven capabilities with Netris Network Automation, Abstraction, and Multitenancy (NAAM).
• The joint solution will enable neoclouds to launch secure, NVIDIA GPU-accelerated IaaS offerings faster, create new revenue opportunities and meet NVIDIA’s technical requirements for delivering multitenant services to neocloud customers.
• Enterprises will be able to run business-critical AI workloads on multitenant GPU infrastructure with hard isolation (enforced on networking hardware) between tenants.
• The combined solution will deliver automation and abstraction across compute and networking, enabling infrastructure to be provisioned and consumed through a cloud-like experience.

Why It Matters
An offering that integrates Nutanix technology with Netris technology will enable neoclouds and enterprises to bring secure, multitenant GPU services to market faster, expand their service offering, and accelerate time to revenue. By simplifying how AI infrastructure is deployed and consumed across bare-metal and virtualized environments, neoclouds will be able to scale more efficiently and improve margins as their business grows.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — NVIDIA GTC – Nutanix (NASDAQ: NTNX), a hybrid cloud leader and AI platform company, and Netris, the leading provider of Network Automation, Abstraction, and Multitenancy (NAAM) for AI infrastructure, today announced a strategic collaboration to deliver a jointly engineered infrastructure stack designed specifically for neoclouds and enterprises. By combining Nutanix Cloud Platform and Nutanix’s expertise in cloud infrastructure and compute orchestration with the Netris NAAM platform, the joint solution will provide neoclouds and enterprises with a scalable, secure, and multitenant solution across the infrastructure.

As the demand for AI infrastructure accelerates, neoclouds and enterprises are leading the deployment of large GPU clusters to support a broad range of AI workloads. Delivering this infrastructure as a service requires both soft isolation and hard isolation (enforced on networking hardware) that extends across every layer of the infrastructure, from the compute layers and data processing units to the physical switches.

An Automated Multitenant Infrastructure Stack for AI Clouds

Bringing together Nutanix’s cloud infrastructure capabilities with Netris network automation and multitenancy, the joint solution will provide neoclouds and enterprises with a secure, multitenant AI infrastructure stack across bare-metal and virtualized environments, enabling providers to instantly onboard customers, maintain strict isolation between tenants from compute through the physical network, and deliver AI services through a cloud-like self-service experience.

Key highlights of the joint solution for neoclouds and enterprises will include:

• Automated Network Fabric Operations: Simplifies AI infrastructure deployment by automatically configuring the physical network as tenant resources are provisioned, reducing manual effort, accelerating time to value, and improving operational consistency.
• Unified Multitenant Networking: Delivers a consistent networking experience across physical and virtual environments by translating Nutanix tenant requirements into the appropriate underlying network services for bare-metal and virtualized GPU nodes.
• Self-Service Cloud Networking: Provides cloud-grade networking constructs — VPCs, elastic IPs, NAT, and L4 load balancers — through a web console, REST API, and Terraform, enabling infrastructure to be consumed through a self-service, cloud-like experience.
• High-Performance AI Factory Networking: Supports the connectivity for demanding AI workloads, enabling efficient edge, East-West, North-South, scale-up, and host-based networking traffic flows.
• End-to-End Tenant Isolation: Extends secure hard and soft tenant isolation across the entire network — from virtual workloads through the physical switching layer — supporting secure, reliable GPU-as-a-Service offerings on shared infrastructure.

Executive Commentary

“Neoclouds and NVIDIA Cloud Partners are at the forefront of the AI transformation, but building the cloud operating stack required to monetize GPU clusters at scale is remarkably complex,” said Ketan Shah, Vice President, Product Management, Nutanix. “By pairing Nutanix’s Agentic AI solution with the Netris NAAM platform, we will provide AI cloud operators with an out-of-the-box solution to accelerate their journey from metals to margins. We chose to partner with Netris, a leader in network automation, abstraction, and multitenancy, to give operators true self-service networking across both bare-metal and virtualized environments. This will enable our partners to deliver secure, multitenant IaaS environments quickly while maintaining the simplicity and enterprise reliability that Nutanix is known for.”

“AI infrastructure is scaling incredibly fast, and the network has to scale with it,” said Alex Saroyan, CEO and Co-Founder of Netris. “An AI cloud needs two layers working as one — Nutanix’s compute orchestration and virtualization, backed by deep operational leadership and experience, and Netris network automation, abstraction, and multitenancy. What makes this collaboration matter is that those layers stay continuously in sync, giving neoclouds and enterprises a single automated stack for secure, multitenant GPU services.”

Analyst Commentary

“AI infrastructure providers are evolving beyond GPU capacity to deliver trusted inference environments, workload orchestration, agent lifecycle management, and managed AI services. The differentiator will be a cloud-like operating model that combines performance with control, isolation, and security at every layer of the stack.”

• Steve McDowell, Principal Analyst, NAND Research

Availability

The joint solution is planned to be available in tech preview in early 2027.

About Nutanix

Nutanix is a hybrid cloud leader and AI platform company, offering organizations a unified infrastructure software platform to safely run applications, data, and AI anywhere. Trusted by customers worldwide, Nutanix empowers more than 50% of the Global 2000 to innovate faster with AI, while modernizing infrastructure, simplifying operations, and controlling costs. Learn more at www.nutanix.com or follow us on social media.

About Netris

Netris is the leading provider of network automation and multitenancy for AI infrastructure, purpose-built for neoclouds, sovereign AI operators, and AI factories. The Netris NAAM (Network Automation, Abstraction, and Multitenancy) platform delivers network orchestration for AI clusters, hard multitenancy enforced on networking hardware, and cloud-provider-grade automation across Ethernet, InfiniBand, DPUs, and virtual and edge networking — from Day Zero design and simulation through live operations. Netris enables operators to launch GPU clouds in weeks, provision tenants instantly with isolation configured automatically, and maximize GPU utilization by dynamically reallocating capacity across tenants. Netris is the most widely deployed network automation platform for AI clusters, with 70+ live deployments. Founded in 2018 and backed by Andreessen Horowitz, Netris is headquartered in Santa Clara, California. Learn more at netris.io.

©2026 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo and all Nutanix product and service names mentioned are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. All other brand names mentioned are for identification purposes only and may be the trademarks of their respective holder(s).

This content may contain express and implied forward-looking statements, including but not limited to statements regarding our plans and expectations relating to new product features and technology under development, the capabilities of such product features and technology, and our plans to release product features and technology. Such statements are not historical facts and are instead based on our current expectations, estimates and beliefs, including statements about The accuracy of such statements involves risks and uncertainties and depends upon future events, including those that may be beyond our control, and actual results may differ materially and adversely from those anticipated or implied by such statements, including, among others: failure to develop, or unexpected difficulties, delays or disruptions in developing, releasing or distributing, new products, services, product features or technology in a timely or cost-effective basis. Any forward-looking statements included speak only as of the date hereof and, except as required by law, we assume no obligation to update or otherwise revise any such forward-looking statements to reflect subsequent events or circumstances. Certain products and features or functionalities described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The development, release, and timing of any such products, features or functionalities are subject to change. Nutanix will not have any liability for any failure to deliver or delay in the delivery of any such products, features or functionalities. Any future product or product feature information is intended to outline general product directions, and is not a commitment, promise, or legal obligation for Nutanix to deliver any functionality. This information should not be used when making a purchasing decision.

CONTACT: Contacts

Nutanix
Ken Lotich
pr@nutanix.com

Netris
Jason Klein
pr@netris.io

Findings suggest a dual mechanism of action for REYOBIQ against cancer cells

New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers

HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”) today announced that new preclinical data presented at the 16^th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational targeted radiotherapeutic. The Ovarian Cancer Research Alliance sponsored the symposium, held October 16–18, 2026, in Philadelphia. In two mouse models of aggressive epithelial ovarian cancer, treatment with rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL), the active agent in REYOBIQ, was associated with tumor injury and changes in the tumor microenvironment. Combination treatment with anti-PD-1 checkpoint blockade also showed improved antitumor activity.

“Turning ‘cold’ or immunologically resistant tumors into ‘hot’ or immunologically responsive tumors is the major limitation for the broader use of checkpoint inhibitors,” said Eric J. Daniels, M.D., Cerenome’s Chief Development Officer. “REYOBIQ delivers targeted radiation that injures the tumor, activates further DNA-damage, p53, and apoptosis programs within 24 hours, turning on the innate immune response, while simultaneously lowering IL-10 and macrophage-driven immunosuppression. This sequence may convert cold tumors like ovarian, pancreatic and many CNS cancers, into hot ones. This opens up new combination strategies for these patients. Cerenome, along with its academic collaborators, are now characterizing REYOBIQ’s immunomodulatory activity further across a board range of tumors.”

More Than a Dose of Radiation

REYOBIQ is designed to deliver a very high dose of beta radiation directly to the tumor or the fluid compartment around it, while minimizing exposure to the rest of the body. Its well-established mechanism of action is radiation-induced DNA damage and tumor cell death. A growing body of translational evidence suggests REYOBIQ may also act substantially on the immune system. In this proposed sequence, local radiation injures tumor cells that then triggers interferon signaling, antigen presentation, cytotoxic T cell and natural killer (NK) cell recruitment to the tumor environment, and dampens immunosuppressive signals.

Ovarian Cancer Models Illustrate the Mechanism

Henriette Balinda, Ph.D., and colleagues in the laboratory of Andrew Brenner, M.D., Ph.D., at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) presented the poster, titled, “186Rhenium-Nanoliposome (186RNL) Remodels the Tumor Microenvironment in Preclinical Ovarian Cancer Models.” Epithelial ovarian cancer responds poorly to checkpoint inhibitors given alone, in part because its tumor microenvironment suppresses the immune system. That makes it an attractive model for testing whether local radiation can reverse that suppression. The poster also tracked immune changes in ascites (abdominal fluid).

The poster will be available on the Publications page of Cerenome’s website.

Key scientific findings:

• Tumor injury starts the response: Single-cell RNA sequencing showed that DNA-damage, p53 and apoptosis (cell-death) programs switched on within 24 hours of treatment.
• The immune system is then activated: By Day 28, interferon signaling, innate immunity, and antigen-presentation programs had increased, and macrophage-associated immunosuppressive programs had decreased.
• Lower immunosuppressive signaling: 186RNL substantially lowered IL-10, an immunosuppressive cytokine, compared with untreated controls.
• Effector immune cells shift the balance: When 186RNL was combined with anti-PD-1, immune cells (CD45+), T cells (CD3+), CD8+ cytotoxic T cells, CD4+ effector T cells, and NK cells all rose, while monocytes fell. The immune response was dominated by CD8+ T cells. It peaked at 24 hours and lasted through Day 28. CD8+ T-cell activation markers (CD25 and CD69) were higher with the combination than with anti-PD-1 alone.
• Dose-dependent antitumor activity: In the ID8agg model, 186RNL improved survival in a dose-dependent manner across doses of 0.075 to 1.257 mCi (p = 0.0003). Bioluminescence imaging showed the deepest and longest-lasting tumor suppression at the highest dose.
• Better outcomes with checkpoint blockade: 186RNL plus anti-PD-1 extended median survival to 65 days, longer than control or either agent alone. The combination also reduced tumor burden, and tissue samples showed minimal remaining tumor in the omentum. Weight loss was brief, and the combination showed no evidence of substantial added toxicity.

“Ovarian cancer has responded poorly to checkpoint inhibitor monotherapy, in part because the tumor environment suppresses the immune system,” said Andrew Brenner, M.D., Ph.D., Professor-Research, Kolitz Chair in Neuro-Oncology, UT Health San Antonio. “In these models, REYOBIQ or 186RNL caused early DNA damage in tumor cells, followed by interferon signaling and immune activation. The combination with anti-PD-1 increased CD8+ T cells and NK cells and lowered immunosuppressive signals. Those are the changes you want to see and support an understanding of how REYOBIQ may be used in the future to make checkpoint therapy more effective.”

About REYOBIQ™ (rhenium Re186 obisbemeda)

REYOBIQ is an investigational injectable radiotherapeutic in which the radioisotope rhenium-186 is chelated and trapped inside a nanoliposome. It is designed to deliver targeted, high-dose beta radiation directly to tumors through local delivery, such as convection-enhanced delivery or an intraventricular (Ommaya) catheter, while keeping exposure to the rest of the body low. REYOBIQ is being evaluated for the treatment of leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers in the ReSPECT-LM, ReSPECT-GBM and ReSPECT-PBC clinical trials. Results from the multicenter Phase 1 ReSPECT-GBM trial were published in Nature Communications in 2025 (Brenner AJ, et al. Nat Commun. 2025;16:2079). REYOBIQ is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for any use.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “may,” “could,” “suggest,” “support,” “plan” and similar expressions or the negatives thereof. These statements include, without limitation, statements about the potential immunomodulatory properties of REYOBIQ and rhenium (186Re) obisbemeda; the potential of REYOBIQ to change the tumor immune microenvironment or improve response to immune checkpoint inhibitors; the potential of REYOBIQ in combination with immunotherapy in CNS cancers or other indications; whether preclinical results will be reproduced in further preclinical studies or in human clinical trials; and the Company’s research and clinical development plans for REYOBIQ. These statements are based on assumptions and assessments made by management in light of their experience, their view of historical trends, current conditions, expected future developments and other factors they believe are appropriate. Preclinical results may not predict clinical outcomes. Actual results could differ materially because of risks and uncertainties, including those described under “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Investor Contact
CORE IR
IR@cerenome.com

A PDF accompanying this announcement is available at http://ml.globenewswire.com/Resource/Download/b41783e3-1ede-4509-a02d-c887a38bcfd6

Recently completed C$70.4 million financing has strengthened balance sheet; permitting advancing for Bellville, Texas production facility; securityholder vote on Delaware redomicile set for October 29; lead commercial opportunities move into negotiation with closings expected within months; defense division advancing multiple U.S. opportunities

AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (“HydroGraph” or the “Company”) today provided a corporate progress update on its 2026 objectives, including a strengthened balance sheet following its upsized C$70.4 million bought deal financing, advancement of its planned Texas large-scale graphene manufacturing facility and the upcoming special meeting of securityholders to approve its proposed redomicile to the United States.

“We are executing on our plan to move HydroGraph from technology development to commercial production,” said Kjirstin Breure, President and Chief Executive Officer of HydroGraph. “At the start of 2026, we set a clear series of goals for this transition, and we have now achieved most of them, including securing U.S. EPA and UK and EU REACH regulatory clearances, opening our new Austin headquarters with three Hyperion Reactors on site, launching our high-concentration Fractal Graphene Paste™, and securing both the site for our large-scale manufacturing facility in Bellville, Texas and a long-term acetylene supply agreement with Western International.

“With these milestones in place, we believe that HydroGraph is increasingly positioned to supply high volumes of pristine graphene for industrial-scale applications. Our two remaining 2026 goals are securing our first commercial purchase orders and advancing our work with the U.S. federal government. Both are on moving forward.

“On the commercial side, multiple of our most advanced customer engagements have moved from evaluation to commercial negotiation, and we expect to enter into the first of those agreements within the coming months. In parallel, we are advancing a dedicated defense division focused on highly engineered graphene solutions for the U.S. military and other federal interests. These initiatives have the potential to provide both near-term revenue opportunities upon commencement of a program and larger longer-term opportunities as solutions progress toward qualification and deployment.”

Key 2026 milestones to date include:

• Closing of an upsized bought deal offering on August 25, 2026, for gross proceeds of C$70.4 million, including full exercise of the over-allotment option, at C$6.80 per unit, the highest offering price in the Company’s history.
• Appointment of Grant Thornton as the Company’s auditor beginning with fiscal year 2026, as part of the Company’s redomiciling to the United States.
• Filing and mailing of the management information circular for a Special Meeting of Securityholders to be held October 29, 2026, to approve the redomicile of HydroGraph to the United States as a Delaware corporation.
• Receipt of a certificate of occupancy for the Austin headquarters, bringing both the administrative and development/production areas of the facility to full operational status. With three on-site Hyperion Reactors, the facility has capacity of up to 30 tons of graphene per year. The Company celebrated the opening with a visit from U.S. Representative John Carter (TX-31).
• Initial steps with government, industry and research partners to create a dedicated U.S. graphene innovation consortium comparable to the Graphene Engineering Innovation Centre (GEIC) at the University of Manchester in the United Kingdom. HydroGraph is taking a leadership role in steering its development. The innovation center is being structured to serve aerospace, defense and national security interests; the Company’s defense research partnerships are expected to accelerate its development.
• Advancement of permitting for the Bellville, Texas manufacturing facility, which is expected to open in the first half of 2027 with initial capacity of approximately 60 tons per year, then anticipated to scale to approximately 360 tons per year in the first phase and more than 750 tons per year in the second phase. The facility will receive acetylene feedstock by dedicated pipeline under a 10-year supply agreement with Western International.
• Commercial launch of Fractal Graphene Paste™, a water-based dispersion containing 20% graphene by weight, compared with approximately 1% to 5% for typical commercial graphene dispersions, and a shelf life of more than two years. More than 30 customers have received samples for evaluation in applications including coatings, concrete and construction materials, thermal management and elastomers.
• Advancement of the Company’s commercial pipeline, with multiple of the most advanced customer evaluations now moving from technical qualification and scale up into commercial negotiation. These discussions cover pricing, volumes and supply terms, and the Company expects the first of these opportunities to convert into purchase orders or supply agreements within the coming months.
• Advancement of the Company’s defense division, which is focused on highly engineered graphene solutions for U.S. national security interests. The Company is in active negotiations for multiple research partnerships that include funding for the work to be performed. Some programs require specialized research and development and carry longer development cycles than the Company’s commercial applications, with defined milestones that the Company expects to announce as they are achieved. The Company sees revenue opportunities from these initiatives that are both immediate upon commencement of a program and longer term as solutions progress toward qualification and deployment.
• Expansion of the Company’s intellectual property portfolio across multiple jurisdictions, with new patent applications filed or in preparation covering recent HydroGraph innovations and products.
• Continued expansion of the HydroGraph team, particularly in research and production roles, to support increasing commercial activity and the ramp to full production at the Bellville facility.

The Company has granted (the “Grant”), as part of the compensation committee’s review of long-term incentive awards, an aggregate of 1,268,133 restricted share units (the “RSUs”) and 218,691 stock options (the “Options”) to certain directors, officers, employees and consultants of the Company under its Share Compensation Plan. All of the RSUs and Options vest as to one-third every year from the date of Grant, other than 143,291 RSUs granted on October 13, 2026 to certain directors, which vest as to one-third on each of October 13, 2027, October 13, 2028 and October 13, 2029, provided that 45,867 of such RSUs granted to a certain director vest as to one-third on each of October 13, 2027, September 17, 2028 and September 17, 2029. Each vested RSU entitles the holder to receive one common share in the capital of the Company (each, a “Share”), or the equivalent cash value thereof, in accordance with the terms of the Company’s Share Compensation Plan. Each Option can be exercised for one Share at a price of $2.78 per Share for a period of five years from the date of Grant. All RSUs and Options, including any Shares issued upon the exercise or settlement thereof, are subject to a hold period of four months and one day from the date of Grant.

The Company has also granted (the “CEO Grant”), as part of the compensation committee’s annual review of executive compensation and long term incentive awards, 625,000 restricted share units (the “CEO RSUs”) and 625,000 options (“CEO Options”) to Kjirstin Breure, the President and Chief Executive Officer of the Company. The Company also granted 3,600,000 CEO Options based on the achievement of previously established CEO performance milestones. All of the CEO RSUs and CEO Options, including the CEO Options granted based on the achievement of previously established CEO performance milestones, vest as to one-third every year from the date of the CEO Grant. Each vested CEO RSU entitles the holder to receive one Share, or the equivalent cash value thereof, in accordance with the terms of the Company’s Share Compensation Plan. Each CEO Option can be exercised for one Share at a price of $2.78 per Share for a period of five years from the date of the CEO Grant. All CEO RSUs and CEO Options, including any Shares issued upon the exercise or settlement thereof, are subject to a hold period of four months and one day from the date of CEO Grant.

About HydroGraph
HydroGraph is a leading producer of pristine synthetic graphene using its proprietary Hyperion Reactor technology, which allows for exceptional purity, low energy use, and identical batches. The quality, performance, and consistency of HydroGraph’s graphene follow the Graphene Council’s Verified Graphene Producer® standards, which very few graphene producers are able to meet. For more information or to learn about the HydroGraph story, visit: https://hydrograph.com/. For company updates, please follow HydroGraph on LinkedIn at https://www.linkedin.com/company/hydrograph/ and X at https://x.com/HydroGraphInc.

Trademarks: HydroGraph™, Fractal Graphene™ and Fractal Graphene Paste™

Forward-Looking Statements

This release contains certain “forward-looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “upon”, “anticipate”, “believe”, “continue”, “plans”, “could”, “would”, “should”, “suggests”, “target”, “has the potential to”, “goal”, “on track” or similar terminology. Forward-looking statements in this release include, but are not limited to, statements regarding the timing of first commercial purchase orders; the progress, timing and outcome of commercial negotiations and the Company’s expectation that initial agreements will close within months; the establishment, scope and activities of the Company’s defense division; the negotiation, funding, timing, milestones and revenue potential of defense-related research partnerships; the establishment, development, scope and activities of a U.S.-based graphene innovation organization; the Company’s work with the U.S. federal government; the completion and timing of the proposed redomicile; the receipt of required securityholder, court and other approvals in connection therewith; the Company’s cash position and ability to fund its growth strategy; the operation and production capacity of the Austin headquarters facility and its Hyperion Reactors; the permitting, construction, timing, opening, feedstock supply arrangements and production capacity of the Bellville facility; customer evaluation, qualification and adoption of the Company’s products, including Fractal Graphene Paste™; the anticipated performance, commercial acceptance and market opportunities for the Company’s products; patent filings and intellectual property development; and the Company’s hiring and expansion plans.

Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable, and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of HydroGraph to control or predict, that may cause HydroGraph’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: HydroGraph’s ability to implement its business strategies; the ability to obtain securityholder, court and other approvals required for the redomicile; delays in permitting, construction, commissioning or operation of production facilities; the availability and reliability of feedstock supply; the pace of customer qualification and adoption of graphene products; the risk that commercial negotiations do not result in binding agreements or do not close within the expected timeframe; the risk that anticipated purchase orders, supply agreements or commercial relationships are not obtained on the expected timeline or at all; the Company’s dependence on U.S. government funding, procurement cycles, appropriations and security and export control requirements in connection with its defense initiatives; the extended development cycles associated with defense research programs; risks relating to the establishment and development of a U.S.-based graphene innovation organization; risks associated with general economic conditions; adverse industry events; stakeholder engagement; marketing and transportation costs; loss of markets; volatility of commodity prices; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; industry and government regulation; changes in legislation, income tax and regulatory matters; competition; currency and interest rate fluctuations; and other risks. HydroGraph does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CONTACTS:
Matt Kreps
Senior Vice President of Capital Markets and Investor Relations
+1-214-597-8200
matt.kreps@hydrograph.com

Len Fernandes
Firecracker PR for HydroGraph
len@firecrackerpr.com

Supermicro servers powered by Nutanix Agentic AI are designed for enterprises to fast track deployments of AI infrastructure, secure critical on-premises GPU resources, reduce AI costs, and scale AI workloads with flexibility and control

News Summary

• Nutanix and Supermicro are expanding their collaboration to help enterprises lower the cost per token of private AI inference and accelerate adoption of open-weight models through a planned engineered, full stack infrastructure solution.
• The solution will enable enterprises to accelerate AI inference workloads and facilitate securing critical on-premises GPU resources.
• The solution will combine Supermicro servers with Nutanix Agentic AI full stack software designed to reduce custom-order, configuration, and integration complexity, giving customers a more predictable way to deploy, manage, and scale on-premises GPU infrastructure.

Why it Matters

For customers, this means AI cost control and a faster path to putting production AI to work because of operational simplicity due to less time that will be spent assembling and integrating multivendor environments.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — NVIDIA GTC – Nutanix (NASDAQ: NTNX), a hybrid cloud leader and AI platform company, and Super Micro Computer, Inc. (NASDAQ: SMCI), today announced plans for a jointly engineered AI infrastructure solution powered by Nutanix Agentic AI designed to help enterprises take on runaway AI costs with a system for private inference.

Built on the validated Supermicro systems powered by Nutanix Agentic AI, the solution will combine the Nutanix Cloud Platform with Supermicro servers, NVIDIA GPUs, and NVIDIA Spectrum-X networking. Designed to reduce custom configuration and integration complexity, it will simplify the path from infrastructure deployment to production-ready AI. Nutanix delivers a complete, full-stack AI platform engineered to simplify and accelerate the deployment of enterprise AI workloads — from underlying infrastructure to model execution and the governance of agentic workloads. The solution will help enable seamless provisioning from bare metal to delivering integrated model-as-a-service and a secure Agent Gateway using Nutanix Kubernetes Platform — the Cloud Native Computing Foundation certified AI conformant Kubernetes distribution — and Nutanix Enterprise AI. The solution will be supported by Nutanix Unified Storage (NUS) which provides high-performance NVIDIA Enterprise-certified storage for AI workloads, including context caching and model serving. Together, these capabilities are intended to provide the end-to-end performance, resilience, and orchestration required to support modern AI initiatives. The built-in AI catalog will further simplify deployment by providing access to common AI applications.

As AI requirements grow, the architecture is designed to scale GPU capacity while the dedicated Nutanix control plane and storage services will support resilient operations and high-throughput data workflows. With this engineered offering, customers will be able to more easily deploy, manage, and scale AI inference workloads without having to assemble and connect a complex mix of multivendor technologies.

“Collaborating with Nutanix, we want to accelerate time-to-online for enterprise AI,” said Matthew Thauberger, Chief Revenue Officer, Supermicro. “Combining Supermicro’s engineered servers with Nutanix’s full-stack software will deliver a pre-validated, rack-scale solution that bypasses traditional lead-time delays. It will help give organizations predictable access to high-density GPU compute while removing the operational complexity of scaling AI.”

“Moving AI from experimentation into production remains a challenge for many enterprises, with infrastructure complexity and hardware procurement often slowing progress. Our expanded collaboration with Supermicro is a direct response to this barrier,” said Thomas Cornely, Executive Vice President, Product Management, Nutanix. “The Supermicro systems, engineered with our Nutanix Agentic AI full stack software, will help enterprises simplify how AI infrastructure is deployed, operated, and secured, and scaled, enabling them to simply deploy private inference and control the cost per token as AI adoption scales.”

Supermicro with Nutanix Cloud Platform: Reducing the Complexity of Enterprise AI Infrastructure

• The engineered solution from Supermicro and Nutanix is intended to provide a hardware foundation that helps eliminate custom-order delays by using the Supermicro server systems which houses eight NVIDIA Blackwell Ultra GPUs per node.
• The resilient single-tenant control plane is expected to feature a dedicated, resilient Nutanix management cluster (NX-8170-G10) to protect against management plane failure without disrupting GPU execution.
• For high-performance storage scaling, an integrated NUS cluster (NX-8150-G10) is optimized for high-bandwidth I/O requirements across AI data ingestion, checkpointing, and cache warming.
• NVIDIA Spectrum-X Ethernet networking combines NVIDIA Spectrum-4 Ethernet switches (SN5610/SN5600) with NVIDIA ConnectX-7/8 SuperNICs for high-performance, predictable GPU-to-GPU scale-out connectivity and NVIDIA BlueField-3 DPUs for infrastructure offloading and in-band management, complementing NVIDIA’s scale-in networking architecture.

Analyst Commentary

“The AI imperative is shifting from simply building raw compute capacity to optimizing the cost and efficiency of every inference delivered. Hardware, memory, networking, model optimization, and orchestration all need to be managed as a system if organizations are going to scale inference efficiently and translate AI investment into real business outcomes.”

• Matt Kimball, Vice President & Principal Analyst, Moor Insights & Strategy

Availability

The Supermicro systems powered by Nutanix Agentic AI will be available early 2027 from Supermicro and its channel partners.

About Nutanix

Nutanix is a hybrid cloud leader and AI platform company, offering organizations a unified infrastructure software platform to safely run applications, data, and AI anywhere. Trusted by customers worldwide, Nutanix empowers more than 50% of the Global 2000 to innovate faster with AI, while modernizing infrastructure, simplifying operations, and controlling costs. Learn more at www.nutanix.com or follow us on social media.

About Super Micro Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions provider with server, AI, storage, IoT, switch systems, software, and support services. Supermicro’s motherboard, power, and chassis design expertise further enables our development and production, enabling next-generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Taiwan, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling).

Nutanix Forward-Looking Statements

©2026 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo and all Nutanix product and service names mentioned are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries.

This press release contains express and implied forward-looking statements, including but not limited to statements regarding the expanded collaboration between Nutanix and Supermicro; the planned jointly engineered AI infrastructure solution; anticipated technical integrations; future products, services, features and offerings; anticipated customer benefits; planned technical collaboration and go-to-market activities; customer adoption; the timing, availability and performance of future solutions; and the parties’ ability to successfully finalize and implement commercial arrangements supporting the planned solution relating to the expanded collaboration. These forward-looking statements are based on Nutanix’s current expectations, estimates, assumptions and projections and involve risks and uncertainties that could cause actual results to differ materially. Actual results may differ materially due to a number of factors, including the parties’ ability to finalize and implement commercial arrangements supporting the planned solution, complete anticipated integration efforts, develop and deliver contemplated functionality, successfully execute collaborative activities, achieve customer adoption, and realize the anticipated benefits of the planned solution, as well as other risks and uncertainties described in Nutanix’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other filings. These forward-looking statements speak only as of the date of this press release, and Nutanix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Many of the anticipated products, services, integrations, offerings, features and functionalities described herein remain in various stages of planning, development, testing and implementation and will be offered on a when-and-if-available basis. The development, release and timing of any such products, features or functionalities are subject to change. Nutanix will not have any liability arising from reliance on this press release for any failure to deliver, or delay in the delivery of, any such products, features or functionalities. Any future product or product feature information is intended to outline general product direction and should not be relied upon in making a purchasing decision. Such information is not a commitment, promise or legal obligation to deliver any functionality, offering or integration. The expanded collaboration, planned solution, offerings and related activities described in this press release remain subject to ongoing development efforts and, where applicable, the finalization and implementation of related commercial arrangements between the parties.

CONTACT: Media Contacts:

Nutanix
Ken Lotich
pr@nutanix.com

Supermicro
pr@supermicro.com

Nutanix Is Expanding Its AI Ecosystem with NVIDIA, Supermicro, and Netris to Help Enterprises and Service Providers Quickly Deploy and Scale Production AI, and Reduce AI Costs

News Summary

• Powering Agentic AI with NVIDIA Vera CPU: Nutanix plans to work with NVIDIA toward Day Zero support for Vera, combining its CPU capabilities with Nutanix software. NVIDIA’s high-performance CPU architecture, paired with Nutanix Kubernetes Platform (NKP) on bare metal are expected to provide a predictable, low-latency foundation for running advanced AI agents.
• Accelerating AI Deployment and AI Cost Control with Supermicro: Nutanix and Supermicro are announcing plans for a jointly engineered system combining standardized Supermicro servers with Nutanix’s Agentic AI full stack software, aiming to help customers simplify and accelerate deployment of private inference for increased security and lower token costs.
• Multitenant AI Infrastructure on Bare Metal and Virtualized Environments with Netris: The Nutanix Cloud Platform and Netris Network Automation, Abstraction, and Multitenancy (NAAM) platform will simplify multitenant AI infrastructure with network automation, hard tenant isolation, and self-service network operations across bare-metal and virtualized environments. The integrated solution will enable AI cloud providers to deliver GPU infrastructure as a service through a more unified, cloud-like experience.

Why it Matters

As demand for production AI grows, organizations are under pressure to deploy increasingly complex infrastructure faster and turn AI investments into real business value. Nutanix is working across a broad ecosystem of infrastructure and silicon partners to simplify that path, planning to help enterprises bring production AI and agentic workloads online more quickly while enabling neoclouds and service providers to scale the multitenant AI services they deliver to customers.

Together, these advancements are intended to combine Nutanix software with leading infrastructure technologies to help reduce deployment complexity, accelerate time to value, reduce AI costs, and provide a consistent foundation for operating AI at scale.

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — NVIDIA GTC — Nutanix (NASDAQ: NTNX), a hybrid cloud leader and AI platform company, today announced it is collaborating with NVIDIA, Supermicro, and Netris to deliver new AI solutions that aim to simplify the infrastructure required for production AI and help organizations bring new capabilities online faster. By combining Nutanix software with leading hardware, networking, and silicon technologies, Nutanix aims to help enterprises deploy and operate production AI environments more efficiently at scale.

As organizations push more AI workloads into production, capacity constraints and operational complexity can make it harder to move quickly. Nutanix and its partners are working to simplify that path to make it easier to bring AI into production faster and accelerate time to value.

“Organizations need more than just advanced infrastructure to move agentic AI into production – we believe they need an AI cloud that simply connects intelligence, agents, enterprise applications, and data across CPUs, GPUs, virtual machines, containers, on-premises environments, and cloud,” said Thomas Cornely, Executive Vice President, Product Management at Nutanix. “Through our collaboration with NVIDIA, Supermicro, and Netris, we plan to help customers accelerate deployments of agents and AI services on a unified platform with built-in security, performance, and governance.”

Extending Agentic AI to the CPU Layer with NVIDIA Vera

As enterprises adopt agentic AI at scale, they are anticipated to require infrastructure that can support increasingly demanding workloads across the full AI environment, not just GPU-intensive tasks. Agentic applications combine inference with tool calls, code execution, retrieval, orchestration, and outcome processing. As these workflows scale, CPU performance is expected to become essential for completing the steps between GPU operations, reducing delays, and maximizing overall AI-factory efficiency. To help ensure this critical compute path does not become a bottleneck, Nutanix plans to work towards Day Zero support for NVIDIA Vera CPUs, beginning with NKP Bare Metal, to serve highly performance-sensitive AI factory environments, with planned expansion to virtualized Nutanix environments.

By pairing NVIDIA’s purpose-built CPU architecture – engineered for high-speed agent execution and reduced latency – and NVIDIA OpenShell to create safe, private runtime environments for agents with NKP, the collaboration aims to give organizations a predictable, high-performance foundation for their most advanced AI agents.

This support is expected to give organizations greater flexibility in how they safely deploy agentic AI while simplifying operations with a consistent cloud operating model.

Nutanix and Supermicro Take on Runaway AI Costs with Jointly Engineered System for Private Inference

Nutanix and Supermicro are announcing plans for a jointly engineered AI infrastructure solution built around validated Supermicro server systems. By combining Supermicro servers and NVIDIA GPUs with Nutanix Agentic AI (NAI) and NVIDIA Spectrum-X^TM Ethernet networking, the solution is being designed to help reduce custom configuration and integration delays, with the goal of helping enterprises get on-premises GPU capacity and take on runaway AI costs with a jointly engineered system powered by NAI for private inference.

As AI requirements grow, the architecture is expected to be able to scale GPU capacity to meet evolving requirements. Nutanix provides an AI cloud control plane and AI storage purpose-built to support workloads with resilient operations and high-throughput data workflows. Customers are anticipated to gain a predictable path to deploy, manage, and scale AI inference workloads without assembling and integrating a complex, multivendor environment.

Nutanix and Netris: Making Multitenant AI Infrastructure Easier to Deploy and Operate

For NVIDIA Cloud Partner reference architectures, multitenancy is designed to extend across AI infrastructure, including the physical network. In dynamic neocloud environments, operators also must be able to automate network access and ensure tenant isolation as customers, workloads, and GPU allocations change. Nutanix and Netris are collaborating to automate this network-layer multitenancy and turn complex GPU infrastructure into secure, cloud-like, multitenant AI services.

Nutanix will provide the foundation for compute across virtual machines, containers, CPUs, and GPUs, along with storage, security, Kubernetes, and Nutanix Agent Gateway, model-as-a-service and AI platform services. Netris will provide network automation, abstraction, and multitenancy across the physical network fabric, with hard isolation (enforced on networking hardware) from compute through the physical network. Together, the integrated solution will provide a cloud-like self-service operating experience across bare-metal and virtualized AI infrastructure, helping providers instantly onboard tenants and deliver AI services more efficiently.

Analyst Commentary

“Nutanix built its enterprise business by simplifying virtualized infrastructure and more recently containerized workloads,” said Don Gentile, Analyst, Data Platforms and Resiliency, HyperFRAME Research. “Now it’s extending that expertise to bare- metal AI systems, agent execution, private inference, and multitenant cloud services. Through innovation and targeted partnerships, Nutanix is advancing a common cloud operating model that enterprises and service providers have long wanted: consistent management, automation, and choice across increasingly diverse infrastructure.”

Ecosystem Commentary

“AI agents need fast CPUs to execute code, use tools and process data between model calls,” said Hannah Coutand, Director of Product Marketing for Vera CPU at NVIDIA. “NVIDIA Vera is purpose-built for this work, and our collaboration with Nutanix will help enterprises bring high-performance agentic AI into production with a consistent cloud operating model.”

Customer Commentary

“Digital and AI transformation is a fundamental pillar supporting the Kingdom’s ambitions to build cutting-edge, resilient, agile, and data-driven public services. Through our collaboration with Nutanix, we look forward to exploring how Nutanix’s platform for hybrid cloud computing across multiple environments can support the adoption of AI technologies and help develop national capabilities in advanced cloud and AI technologies.”

– Ministry of Environment, Water and Agriculture (MEWA) – Kingdom of Saudi Arabia

About Nutanix

Nutanix is a hybrid cloud leader and AI platform company, offering organizations a unified infrastructure software platform to safely run applications, data, and AI anywhere. Trusted by customers worldwide, Nutanix empowers more than 50% of the Global 2000 to innovate faster with AI, while modernizing infrastructure, simplifying operations, and controlling costs. Learn more at www.nutanix.com or follow us on social media.

©2026 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo and all Nutanix product and service names mentioned are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. Kubernetes is a registered trademark of The Linux Foundation in the United States and other countries. All other brand names mentioned are for identification purposes only and may be the trademarks of their respective holder(s).

This content may contain express and implied forward-looking statements, including but not limited to statements regarding our plans and expectations relating to new product features and technology under development, the capabilities of such product features and technology, and our plans to release product features and technology. Such statements are not historical facts and are instead based on our current expectations, estimates and beliefs, including statements about our plans to collaborate with NVIDIA, Supermicro, and Netris to deliver new AI solutions and the anticipated capabilities of these offerings, anticipated integrations, collaboration activities, customer benefits, and implementation of contemplated arrangements relating to such offerings. The accuracy of such statements involves risks and uncertainties and depends upon future events, including those that may be beyond our control, and actual results may differ materially and adversely from those anticipated or implied by such statements, including, among others: failure to develop, or unexpected difficulties, delays or disruptions in developing, releasing or distributing, new products, services, product features or technology in a timely or cost-effective basis, failure to complete anticipated integrations or collaboration activities, failure to successfully implement contemplated arrangements relating to such offerings, or failure to achieve the anticipated benefits of such offerings. Any forward-looking statements included speak only as of the date hereof and, except as required by law, we assume no obligation to update or otherwise revise any such forward-looking statements to reflect subsequent events or circumstances. Certain products and features or functionalities described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The development, release, and timing of any such products, features or functionalities are subject to change. Nutanix will not have any liability arising from reliance on this content for any failure to deliver or delay in the delivery of any such products, features or functionalities. Any future product or product feature information is intended to outline general product directions, and is not a commitment, promise, or legal obligation for Nutanix to deliver any functionality. This information should not be used when making a purchasing decision. Certain collaborations, offerings, and related activities described herein remain subject to ongoing development efforts and, where applicable, related commercial arrangements among the parties.

CONTACT: Media Contact:
Ken Lotich
pr@nutanix.com

The agreement expands commercialization of Logia’s fuel integrity solutions for standby power in data centers and other mission-critical facilities.

Tel Aviv, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) — Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW), today announced that its subsidiary, Fort Technology Inc. (Nasdaq: FRTT, TSXV: FORT), through its majority-owned subsidiary, Logia USA Inc. (“Logia USA”), has entered into an exclusive Commercial Distributorship Agreement (the “Agreement”) with Schwab Vollhaber Lubratt, Inc. (“SVL”), a leading Midwest commercial HVAC equipment representative headquartered in Roseville, Minnesota.

Under the Agreement, Logia USA granted SVL the exclusive right to purchase and resell Logia USA’s automated fuel maintenance systems (the “Products”) within certain defined territories (collectively, the “Territories”) comprising the states of North Dakota, Minnesota, Wisconsin and Iowa; the Upper Peninsula of Michigan; and a broad range of counties in Illinois (including Cook, DuPage, Lake, Kane, Will, McHenry and additional counties as set forth in the Agreement).

Under the terms of the Agreement, SVL is also authorized to solicit sales outside the Territories that it identifies and communicates to Logia USA. Logia USA retains the right to designate certain house accounts.

The Agreement represents an important step in the commercialization of Logia USA’s fuel integrity systems in the United States. Logia USA’s automated systems are designed to maintain the quality of diesel fuel stored for standby generators in accordance with American Society for Testing and Materials (ASTM) D975 standards, a critical reliability factor for data centers and other mission-critical facilities.

The Agreement is effective as of October 12, 2026 and will remain in effect until July 31, 2027, unless earlier terminated in accordance with its terms.

About SVL

Founded in 1967, SVL is one of the Midwest’s established manufacturer’s representatives for commercial heating, ventilation, air-conditioning and related mechanical systems. SVL works closely with building owners, architects, engineers and contractors and has significant activity in commercial, healthcare, institutional and data center projects. SVL’s established relationships with consulting engineers, contractors and end-users in commercial, institutional and data center projects across the Midwest provide a strong platform for introducing these solutions into the region’s growing critical infrastructure market.

About Fort Technology

Fort is engaged in the retail sale of consumer products, primarily serving the pest control and remedial repair industries. Fort develops, markets and sells a range of products for both amateur and professional customers under its proprietary brands, including Roshield, Entopest, Rempro and BirdGo. Products are sold primarily through Amazon marketplaces in the United Kingdom and Europe as well as through other online sales channels. Fort currently serves customers throughout the United Kingdom and continental Europe and plans to expand its retail operations into the United States, subject to applicable regulatory approvals, including through the acquisition of Logia USA Inc., a company focused on selling advanced fuel integrity solutions for data centers and other mission-critical facilities in the United States.

About Nexera Technologies Ltd

Nexera Technologies Ltd operates, through its subsidiaries, in the fields of advanced technologies for the global homeland security, or HLS, sector and e-commerce. Its operations are conducted through three principal lines of business: KeepZone AI Inc., or KeepZone, a wholly-owned subsidiary dedicated to distributing and promoting AI-powered homeland security technologies, including 3D imaging and electromagnetic threat detection, perimeter intrusion detection, counter-unmanned aircraft systems, and multi-layered security solutions for critical infrastructure and global markets; Fort Products Limited, a legacy consumer products operation focused on pest control and remedial products, which was sold to Fort Technology Inc., or Fort Technology, in July 2025 in exchange for a controlling equity interest, with the Company having since reduced its stake in Fort while retaining control and strategic involvement in related e-commerce activities; and its ongoing legacy e-commerce activities, consisting of data-driven online retail operations (primarily on the Amazon Marketplace) conducted through the Company’s other wholly-owned subsidiaries, including Smart Repair Pro and Top Rank Ltd.

For more information on Nexera Technologies, visit: https://nexera-tech.io/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate,” or other comparable terms. For example, the Company is using forward-looking statements when discussing the anticipated benefits of the distribution agreement between Logia USA and SVL, including the potential expansion of the commercialization, distribution and sales of Logia USA’s automated fuel maintenance systems in the United States; SVL’s ability to promote and generate sales of such systems within the designated territories and identify additional opportunities outside such territories; the anticipated demand for fuel integrity and standby-power solutions among data centers and other mission-critical facilities; the expected benefits, capabilities and performance of Logia USA’s fuel maintenance systems, including their ability to maintain diesel fuel quality in accordance with ASTM D975 standards and support reliable standby-generator performance; Logia USA’s ability to attract customers, generate sales and expand its market presence; the anticipated growth of the data center and critical infrastructure markets; and the Company’s ability to realize anticipated commercial and strategic benefits from its indirect interest in Logia USA through its ownership of Fort.. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to adapt to significant future alterations in Amazon’s policies; the Company’s ability to sell its existing products and grow the Company’s brands and product offerings; the Company’s ability to meet its expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of conditions in Israel; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”), on April 1, 2026, and the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact

Michal Efraty
Adi and Michal PR-IR
Investor Relations, Israel
michal@efraty.com 

MONTREAL, Oct. 21, 2026 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (TSXV CDPR | OTCQX CDPMF | FRA N8HP | BVL CDPR) (“CDPR” or the “Company“) is pleased to announce that its subsidiary, Cerro de Pasco Resources del Perú S.A.C. (“CDPR Perú“), signed, on October 20, 2026, definitive agreements with Activos Mineros S.A.C. (“AMSAC“) for the acquisition of the Quiulacocha tailings, including the portion located outside the Company’s El Metalurgista concession, together with a surface usufruct of up to 30 years over the land associated thereto (the “Transaction“). The Transaction consolidates the rights over 100% of the Quiulacocha tailings for the Company’s Quiulacocha tailings reprocessing project (the “Project“).

The definitive agreements comprise the Contract for the Transfer of Accumulated Waste for its Economic Reprocessing (the “Transfer Contract“) and the Surface Usufruct Contract (the “Usufruct Contract“, and together with the Transfer Contract, the “Definitive Agreements“), both signed under Public Auction No. 001-2026-AMSAC (the “Auction“), which AMSAC awarded to CDPR Perú as previously announced by the Company on October 12, 2026. AMSAC, a Peruvian state-owned company responsible for the remediation of legacy mining environmental liabilities, called the Auction under Supreme Decree No. 013-2008-EM, which allows it to transfer accumulated mining waste from its closure and remediation projects to the private sector for economic use.

Highlights

• 100% of the Quiulacocha tailings now under CDPR rights
• Surface usufruct over approximately 123 hectares for up to 30 years
• US$6.65 million paid at Closing; US$1.435 million annual usufruct fee thereafter
• Contractual royalty payable to AMSAC, as described below
• Social trust of US$1.04 million upfront and US$260,000 per year during operations
• Next step: reprocessing application to the Ministry of Energy and Mines, then a first Mineral Resource Estimate and the EIA

Guy Goulet, CEO of Cerro de Pasco Resources, commented:

“Signing these agreements secures the part of the Quiulacocha tailings that we did not yet hold. With rights over the entire tailings and a 30-year usufruct over the land, we have the certainty of tenure the Project needs. We thank AMSAC and its Sale Committee for the conduct of the process.”

Assets Acquired

Under the Transfer Contract, CDPR Perú acquired the Quiulacocha tailings, identified as mining environmental liability ID No. 6752, over a residue area of approximately 128.07 hectares in the district of Simón Bolívar, province and department of Pasco (the “Residues Area“), for its economic reprocessing. The transfer covers the tailings only, and excludes the land, plants, infrastructure, acid water treatment systems and other assets owned by AMSAC.

Under the Usufruct Contract, CDPR Perú holds a usufruct over approximately 123.39 hectares within Parcel K, a property of AMSAC registered under entry No. 11003003 (the “Usufruct Area“), including 13 existing ancillary works, among them the main dike, to be used exclusively for the Project. CDPR Perú operates and maintains the works at its own cost, which at the end of the usufruct will remain with AMSAC, together with any permanent works added by CDPR Perú, without compensation. The usufruct runs for the useful life of the Project, up to a maximum of 30 years from the closing of the Transaction, which took place on October 20, 2026 (the “Closing”). Of the Usufruct Area, 42.47 hectares overlap with the El Metalurgista concession, whose holder, CDPR Perú, has pre-existing rights over the tailings within its area. Figure 1 shows the Residues Area with the El Metalurgista concession overlaid, and Figure 2 shows the Usufruct Area.

Figure1. Tailings Residues Area with the overlay of the El Metalurgista concession

Figure 2. Usufruct area

Under the Transfer Contract, CDPR Perú bears the risk of the existence, volume, quality, value and recoverability of the tailings. The Company has not established a mineral resource or mineral reserve for the Quiulacocha tailings in accordance with National Instrument 43-101 respecting Standards of Disclosure for Mineral Projects (NI 43-101).

Manuel Rodriguez Mariategui, President of Cerro de Pasco Resources, commented:

“This is a defining moment for Cerro de Pasco Resources. After years of sustained investment, technical work and strategic determination, we have brought together the property and development rights required to advance Quiulacocha. By consolidating our position across the historic tailings and our 100%-owned El Metalurgista concession, we are laying the foundation for a long-term reprocessing project. This milestone marks a fundamental transition for our Company, from securing strategic assets to advancing their development. We believe Quiulacocha can become a flagship project for responsible resource recovery, environmental remediation and sustainable value creation for our shareholders and the communities of Pasco.”

Consideration and Method of Payment

The consideration for the Transaction is payable entirely in cash, plus applicable taxes, and comprises the following amounts paid at Closing as well as obligations payable during the term of the Definitive Agreements:

Item	Amount (US$, plus taxes)	Agreement
Transfer price, single payment	3,780,000	Transfer Contract
Usufruct premium, final, non-refundable and not adjustable	1,435,000	Usufruct Contract
First annual usufruct fee	1,435,000	Usufruct Contract
Total paid at Closing	6,650,000

Following Closing, CDPR Perú will pay AMSAC the annual usufruct fee of US$1,435,000, plus applicable taxes, each year for the term of the usufruct, and the contractual royalty described below. The consideration under the Usufruct Contract is not subject to renegotiation for supervening economic, technical, environmental or legal circumstances.

From signing of the public deed of the Transfer Contract, CDPR Perú will also pay AMSAC, each quarter, the cost of treating the acid water linked to the Project at AMSAC’s acid water treatment plant, plus a charge of 7% for AMSAC’s management and support activities. Until AMSAC has completed a hydrological and hydrogeological evaluation of the water inflows to the tailings, which it will carry out as soon as technically possible, CDPR Perú will pay the full operating cost of the plant. AMSAC will use the results of that evaluation to determine the origin and volume of the water that requires treatment and the portion of the cost that corresponds to the Project, and to evaluate any compensation, credit or adjustment in favour of CDPR Perú. Any additional cost caused by the Project will be borne by CDPR Perú. The plant remains under AMSAC’s operation, administration and control.

CDPR Perú will also fund a private trust to be constituted within 12 months of signing of the public deed of the Transfer Contract to finance social projects exclusively for the benefit of the populations of the Project’s area of influence. The trust will receive a first contribution of US$520,000 at its constitution, a second contribution of US$520,000 within 45 days of approval of the Project’s environmental impact assessment, the environmental management instrument required for the Project (the “EIA”), and annual contributions of US$260,000 from the start of the operation phase and for the useful life of the Project.

Contractual Royalty

The Transfer Contract provides for a contractual royalty in favour of AMSAC on the reprocessing of the tailings, whether the tailings are sold as they are or treated and sold as concentrates, metals or other products, in Peru or abroad. The royalty is calculated each calendar quarter and paid in US dollars, plus applicable taxes, within two months after the end of the quarter. AMSAC may audit each payment.

The royalty is based on the operating profit from the tailings, meaning revenue less the direct costs of treatment, processing and refining and the selling and administrative expenses attributable to that revenue. The rate applied to operating profit rises with the operating margin on a sliding scale, from 1% of revenue at margins of 36.6% or less to 6% at margins above 80% (see Figure 3). In any quarter, the royalty will not be less than 1% of revenue.

Figure 3. Effective rate of contractual royalty in terms of operating margin

Even though a statutory mining royalty is not applicable in this case, the Transfer Contract nevertheless includes a methodology that takes as its reference Peru’s mining royalty regime under Law No. 28258, as amended by Law No. 29788, in force when the integrated auction rules were approved. The Transfer Contract states that this reference is not dynamic, so later changes to the royalty law do not modify the contractual formula, and that the contractual royalty is a contractual consideration distinct from the statutory mining royalty.

The Transfer Contract does not permit the exploitation, processing, sale or removal of the tailings before approval of the EIA, other than for studies, sampling and mitigation. No royalties will therefore accrue until the Project generates revenue from reprocessing.

Regulatory Matters

No finder’s fee is payable in connection with the Transaction, and no non-arm’s length party of the Company has an interest in AMSAC or in the Transaction. The Transaction remains subject to the acceptance of the TSX Venture Exchange (the “TSXV“).

Next Steps

With the agreements signed, the Project enters its pre-operational phase, which runs until approval of the EIA. The pre-operational work begins with the application for the reprocessing of the tailings to the General Directorate of Mining of the Ministry of Energy and Mines, and is also intended to support a first Mineral Resource Estimate for the Quiulacocha tailings, technical studies, and future submission of the EIA.

Qualified Person

Mr. Alfonso Palacio Castilla, MIMMM / Chartered Engineer (CEng) and Senior Project Manager for CDPR, has reviewed and approved the scientific and technical information contained in this news release. Mr. Palacio is a Qualified Person for the purposes of reporting in compliance with NI 43-101.

About Cerro de Pasco Resources

Cerro de Pasco Resources Inc. is focused on developing its 100%-owned El Metalurgista concession in central Peru, which hosts silver-rich tailings and stockpiles accumulated over more than a century of mining in one of the most prolific polymetallic districts in the Americas. The Company’s strategy is to reprocess historic mining waste to recover value while addressing the long-term environmental liabilities associated with these tailings.

For more information, please visit www.pascoresources.com.

Further Information

Donna Yoshimatsu, VP Investor Relations
Mobile: +1 416-722-2456
Email: dyoshi@pascoresources.com

Forward-Looking Statements

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified using forward-looking terminology such as “plans”, “seeks”, “expects”, “estimates”, “intends”, “anticipates”, “believes”, “could”, “might”, “likely”, “scheduled” or variations of such words or statements that certain actions, events or results “may”, “will”, “could”, “would”, “might”, “will be taken”, “occur”, “be achieved” or other similar expressions.

Forward-looking statements, including the expectations of CDPR’s management regarding the expected benefits of the Transaction, including the combination of the rights acquired with the El Metalurgista mining concession; the payments, royalty, costs and contributions provided for in the Definitive Agreements, and the timing thereof; the constitution of, and the contributions to, the private trust; the cost of acid water treatment payable to AMSAC; the conduct of the pre-operational work within the areas available to the Company; the Company’s compliance with its environmental and mitigation obligations under the Definitive Agreements; the filing, timing and outcome of the reprocessing application before the Ministry of Energy and Mines; the preparation, submission, timing and approval of the EIA; the advancement, timing, scope and completion of work programs at the Project; the preparation and timing of a first Mineral Resource Estimate for the Quiulacocha tailings; the approval of the Transaction by the TSXV; and the timing, outcome and impact of permitting and regulatory processes, are based on CDPR’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of CDPR to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Forward-looking information is based on the opinions, estimates and assumptions of management as of the date of this news release. These assumptions include that the Company will have the funds required for its payment and other obligations under the Definitive Agreements; that the required permits and authorizations will be obtained within the periods set by the Transfer Contract; that the pre-operational work can be carried out within the Usufruct Area and the El Metalurgista mining concession; that the cost of acid water treatment will be determined under Annex 4 of the Transfer Contract and that the plant will remain available to the Project; and that the contractual royalty will be the only royalty payable on the tailings, including those located within the El Metalurgista mining concession.

Forward-looking statements are subject to business and economic factors and uncertainties and other factors that could cause actual results to differ materially from these forward-looking statements, including the risk of termination of the Transfer Contract if the reprocessing authorization is not obtained within one year of the application; the requirement to obtain approval of the EIA within 36 months of signing, which AMSAC may extend at its discretion by up to 12 months on request; risks related to the guarantee-enforcement and termination provisions of the Definitive Agreements, including the pre-operational performance guarantee and the penalties under the Transfer Contract, under which amounts paid to AMSAC are not refundable; the risk of increases in the cost of acid water treatment, delays in AMSAC’s hydrological and hydrogeological evaluation or an outcome of that evaluation that does not reduce the portion of the cost borne by CDPR Perú, and restrictions on the availability of the plant; a determination by the competent authorities that the statutory mining royalty applies to any part of the Project, including tailings located within the El Metalurgista mining concession, in addition to the contractual royalty; additional authorizations required to coordinate the rights under the El Metalurgista concession with the agreements over the overlapping area; access or permit restrictions affecting the pre-operational work; delays in permitting; and the risk factors set out in CDPR’s public documents, available on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

The Company has not established a mineral resource or mineral reserve for the Quiulacocha tailings in accordance with NI 43-101 respecting Standards of Disclosure for Mineral Projects. Ongoing drilling, assay, metallurgical and related technical work are intended to support a first Mineral Resource Estimate and future technical studies; there can be no assurance that any such estimate or study will be completed or, if completed, that it will support the advancement of the Project.

Although CDPR believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements and forward-looking information. Forward-looking information is provided as of the date of this news release. Except where required by applicable law, CDPR disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/b70e6194-f4fa-43b6-817f-1899b37aa70c
https://www.globenewswire.com/NewsRoom/AttachmentNg/c752c2b3-b452-4837-b2cd-a03f227dcd8d
https://www.globenewswire.com/NewsRoom/AttachmentNg/f042f2ee-9ff8-477a-ba7f-9aeb82e30053

This press release was published by a CLEAR® Verified individual.

New solution links in-store purchase activity to persistent identities, helping merchants recognize previously unknown shoppers

CHICAGO, Oct. 21, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today announced the launch of Transaction Matching, a solution that connects transaction activity to persistent, privacy-conscious customer identities. The offering leverages Fiserv’s Unknown Shopper solution to help merchants recognize previously unidentified shoppers, including loyalty members who paid with a new card, or shoppers who paid using tap-to-pay or mobile wallet.

Merchants can then enrich pseudonymized customer profiles with demographic and lifestyle insights to better understand purchasing behavior and deliver more relevant offers.

“Transaction Matching helps merchants recognize more of the customers they already serve,” said Brian Silver, EVP of Global Marketing Solutions at TransUnion. “By connecting transaction activity with pseudonymized customer profiles, merchants can reduce duplicate records, better understand the customer journey and apply those insights across advertising, analytics and measurement.”

This is the first collaboration under TransUnion’s broader Transaction Matching solution, giving merchants a new way to unlock the value of customers who have traditionally been overlooked. It empowers merchants and brands to:

• Bring unknown shoppers into focus: Connect previously unidentified in-store transactions to persistent customer identities.

• Separate new customers from repeat customers: Identify returning customers who use a different payment card and measure new-customer acquisition more accurately.

• Enrich customer profiles: Add demographic and lifestyle insights to help improve customer analysis and engagement.

• Reduce payment method blind spots: Associate different card-based payment methods, inclusive of debit and credit card dip and swipe, tap-to-pay, and mobile wallet, with a single customer profile.

“Before partnering with TransUnion and Fiserv, a new credit card could look like a new customer, even when it belonged to a loyalty member,” explained Alisa Stewart, Director of Customer Relationship Management at Red Lobster. “Now we can easily distinguish new customers from returning guests and combine behavioral and demographic insights to better understand and engage them.”

Connecting customer intelligence across commerce and advertising
The collaboration connects complementary transaction and identity capabilities across the advertising and commerce ecosystems. This gives merchants a more complete view of customer activity while maintaining privacy-conscious controls.

“Many merchants have an incomplete view of their customers because transactions can appear disconnected across cards and payment methods,” said Prasanna Dhore, Chief Data Officer at Fiserv. “By working with TransUnion, we’re helping brands like Red Lobster recognize more of the customers already transacting with them, distinguish new customers and turn those insights into smarter marketing and growth decisions.” 

To learn more about TransUnion’s Marketing Solutions, click here.

About TransUnion (NYSE: TRU)
TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments, we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.
http://www.transunion.com/business

Contact	Dave Blumberg TransUnion
E-mail	david.blumberg@transunion.com
Telephone	312-972-6646

Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies 

Deep B-cell depletion demonstrated with a single dose supports the potential for broad immune reset enabled by miv-cel’s unique construct

Consistent, well-tolerated safety profile with no high-grade CRS or ICANS, and no cases of IEC-HS in one-year follow-up

Data further strengthens SPS BLA package and supports potential for miv-cel to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune diseases

EMERYVILLE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced the full one-year data set from KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS). The data will be presented today at MS Toronto 2026, the joint ACTRIMS-ECTRIMS meeting.

“The totality of the one-year durability data from the KYSA-8 trial is very encouraging and suggests miv-cel has the potential to fundamentally change how we treat stiff person syndrome, a progressive, disabling disease with no approved therapies,” said Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine, Céline Dion Foundation Endowed Chair, and lead investigator of the KYSA-8 trial. “The positive primary endpoint results, together with the secondary and exploratory endpoint data, highlight the full clinical benefit of miv-cel with a single dose. Through one year, patients experienced significant improvements across multiple measures of disease burden, including disability, mobility, stiffness, hypersensitivity, physical functioning and mental health, with a well-tolerated safety profile.”

Poster Presentation:
Title: 1-Year Analysis of KYSA-8: the Pivotal, Multicenter, Phase 2 Study of Miv-cel (Mivocabtagene Autoleucel; Formerly KYV-101) CD19 CAR T-Cell Therapy in Stiff Person Syndrome
Presenter: Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine
Poster ID: P0364
Date & Time: Wed., October 21, 2026, 4:30 – 6:30 PM ET

As reported at AAN 2026, the primary endpoint and all key secondary endpoints were achieved with statistical significance in KYSA-8. The one-year durability data being presented today further strengthens these positive results.

Efficacy highlights from one-year follow-up data on 26 patients include:

• Significant improvement in the timed 25-Foot Walk (T25FW) sustained at one year (p < 0.0001): median improvement from baseline of 46% at week 16 (primary endpoint) and 49% at one year.
• At 16 weeks and one year after receiving miv-cel, 81% (21/26) and 77% (20/26) of patients achieved clinically meaningful improvement (≥20% reduction from baseline) in T25FW, respectively, demonstrating sustained benefit for the vast majority of patients.
• Over one-third of patients completed T25FW in <5 seconds, comparable to a typical time for healthy adults.
• Of the 12 patients requiring a walking aid prior to treatment, 67% (8/12) continue to not require assistance.
• 92% (24/26) of patients remained free of chronic immunotherapies for SPS.
• At one year, the trial continued to meet all secondary endpoints, with significant mean improvements from baseline in Modified Rankin Scale, Hauser Ambulation Index, Distribution-of-Stiffness and Heightened Sensitivity Scale, of -1.0 (p = .0003), -1.7 (1.38; p < .0001), -1.6 (1.75; p < .0001) and -2.8 (2.11; p < .0001), respectively.

Exploratory endpoints, including additional efficacy measures continue to support miv-cel’s differentiated clinical profile:

• In the 6-minute walk test, responses deepened over time, with the median improvement in walking distance increasing from 89 meters at the 16-week primary endpoint measurement to 119 meters at one year, a nearly 6-fold improvement over the clinical minimally important change of 20 meters.
• Sustained clinical benefit at one year in physical functioning and mental health, comparable to healthy adults, across the 36-item short form health survey.
• B-cell reconstitution was observed with sustained efficacy and antibody reduction.

Miv-cel continued to demonstrate a well-tolerated safety profile, supporting its potential for outpatient administration:

• No high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).
• Grade 3/4 neutropenia, an expected adverse event (AE) with lymphodepletion and CAR T-cell therapies, was observed in five patients and was manageable.
• Serious treatment-related AEs occurred in three patients, all of which have fully resolved.

“This is a remarkable data set, demonstrating consistent and durable clinical benefit across primary, secondary, and exploratory endpoints, with a well-tolerated safety profile,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “These results reinforce miv-cel’s potential best-in-class clinical profile, which may meaningfully change the trajectory of stiff person syndrome with a single dose, while allowing patients to remain free of chronic immunosuppressive therapies. We look forward to bringing this transformative therapy to patients as quickly as possible.”

About KYSA-8 Registrational Clinical Trial
KYSA-8 is a single-arm registrational Phase 2 trial in which 26 adult patients with SPS, who had an inadequate response to at least one immunotherapy treatment, received a single dose of miv-cel. The primary endpoints are the change from baseline in the T25FW at 16 weeks and the incidence and severity of adverse events (AEs). Secondary endpoints measuring disability, stiffness, hypersensitivity, and mobility include the Modified Rankin Scale (mRS), Distribution-of-stiffness Index (DSI), Heightened Sensitivity Scale (HSS), and Hauser Ambulation Index (HAI), respectively.

About miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.

About Stiff Person Syndrome (SPS)
SPS is a rare, progressive neurologic autoimmune disease characterized by muscle stiffness and painful muscle spasms, impacting mobility and gait. Stiffness, rigidity, and spasms in the torso, arms, and legs lead to progressive disability causing up to 80% of patients to lose mobility, requiring walking aid assistance or wheelchair use^1-3. SPS has been shown to lead to permanent disability and increased risk of mortality³. Most patients with SPS have antibodies to glutamic acid decarboxylase 65 (GAD65) or the glycine receptor, which disrupt normal inhibitory neurotransmission, contributing to the hallmark symptoms of SPS. There are currently no FDA-approved treatments for SPS. Current treatment options include symptomatic treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, as well as supportive care and physical, speech, occupational, and psychiatric therapy; however, the majority of patients have inadequate or no response to these treatment options. An estimated 6,000 patients are diagnosed with SPS in the United States^4-5.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy’s potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential for a single dose of miv-cel to provide a broad immune reset; miv-cel’s potential to fundamentally change how stiff person syndrome is treated; miv-cel’s potential outpatient administration; miv-cel’s potential best-in-class clinical profile; miv-cel’s potential to meaningfully change the trajectory of stiff person syndrome with a single dose while allowing patients to remain free of chronic immunosuppressive therapies; the potential for miv-cel to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose or to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; the possibility that miv-cel may be the first approved treatment for patients with SPS or the first approved CAR T-cell therapy for autoimmune diseases; Kyverna’s pipeline opportunities; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com

¹ Rakocevic G, et al. BMC Neurol. 2019;19:1.
² Dalakas MC. Nat Rev Neurol. 2024;20(10):587-601.
³ Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165.
⁴ Crane PD, et al. Neurology. 2024;103(12):e210078.
⁵ Analysis of 2024 Komodo U.S. Claims Data.

VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) — Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”) is pleased to announce its participation in several upcoming investor conferences across North America and Europe, where Chair and CEO Ivan Bebek will highlight the Company’s corporate strategy and planned Phase 2 drill program at its flagship copper-gold Sombrero Project in Peru, as the Company advances preparations for its next phase of exploration.

Following the recent approval of its expanded Environmental Impact Assessment – Semi-detailed (“EIA-Sd”) and the execution of a drilling contract with AK Drilling International S.A., the Company is advancing the final steps required to obtain its start-of-activities authorization, the final regulatory approval required to commence drilling, while drill pad construction is already underway. The planned program will initially focus on expanding known copper-gold mineralization and testing multiple high-priority targets across the expanded permitted area.

Upcoming Investor Conferences and Presentations

Kinvestor Day 2026 Virtual Investor Conference

• Date: Thursday, October 22, 2026
• CEO Presentation: 11:40 a.m. PT / 2:40 p.m. ET
• Format: 12-minute corporate presentation followed by a live Q&A session
• Registration: Kinvestor Day 2026

Curzio One Wealth Forum

• Date: Monday, October 26, 2026
• CEO Speaking Engagement: 2:25 p.m. ET (Tavistock Ballroom C & D)
• Location: Pier Sixty-Six, Fort Lauderdale, Florida
• Format: Ivan Bebek will join Frank Curzio on stage to discuss the copper market, the growing importance of new discoveries, opportunities across the mining sector and Coppernico’s upcoming exploration plans.
• Event Website: Curzio One Wealth Forum

Red Cloud Fall Mining Showcase 2026

• Dates: October 28–29, 2026
• CEO Presentation: Thursday, October 29, at 11:20 a.m. ET (Kensington Room)
• Location: Omni King Edward Hotel, Toronto, Ontario
• Format: Corporate presentation and investor meetings
• Event Website: Red Cloud Fall Mining Showcase

Precious Metals Summit Zurich 2026

• Dates: November 9–11, 2026
• CEO Presentation: Wednesday, November 11, at 2:15 p.m. (Room 2)
• Location: Park Hyatt, Zurich, Switzerland
• Format: Corporate presentations and one-on-one meetings with institutional investors and industry participants
• Event Website: Precious Metals Summit Zurich

121 Mining Investment London

• Dates: November 23–24, 2026
• Location: Convene, 133 Houndsditch, London, United Kingdom
• Format: One-on-one meetings with institutional investors, fund managers and mining sector participants
• Event Website: 121 Mining Investment

Management will be available for meetings with investors, analysts and industry participants during the upcoming conferences. Investors interested in arranging a meeting are encouraged to contact the Company at info@coppernicometals.com.

For additional information on Coppernico’s upcoming events, please visit www.coppernicometals.com.

Technical Disclosure and Qualified Person

The scientific and technical information contained in this news release was reviewed and approved by Tim Kingsley, M.Sc., CPG, Coppernico’s Vice President of Exploration, who is a “Qualified Person” as defined in NI 43-101.

ON BEHALF OF THE BOARD OF DIRECTORS

Ivan Bebek
Chair & CEO

For further information, please contact:

Coppernico Metals Inc.
Phone: +1 778 729 0600

Email: info@coppernicometals.com    

Website: www.coppernicometals.com

Twitter: @CoppernicoMetal

LinkedIn: www.linkedin.com/company/coppernico-metals/

About Coppernico

Coppernico is a mineral exploration company focused on creating value for shareholders and stakeholders through diligent project evaluation and exploration, in pursuit of the discovery of large-scale, high-grade copper-gold deposits in the Americas. The Company’s management and technical teams have a successful track record of raising capital, discovery and the monetization of exploration successes. The Company’s objective is to become a leading advanced copper and gold explorer, and through its wholly owned Peruvian subsidiary Sombrero Minerales S.A.C., is currently focused on the Ccascabamba (previously referred to as Sombrero Main) and Nioc target areas within the Sombrero Project in Peru, its flagship project, while regularly reviewing additional premium projects to consider for acquisition.

The Sombrero Project is a land package of approximately 57,000 hectares (570 square kilometres) located in the north-western margins of the world-renowned Andahuaylas-Yauri trend in Peru. It consists of a number of prospective exploration targets characterized by copper-gold skarn and porphyry systems and precious metal epithermal systems. The Company’s NI 43-101 technical report, with an effective date of April 17, 2024, and as filed on SEDAR+ on May 23, 2024, focuses on the Ccascabamba and Nioc target areas of the Sombrero Project.

Common shares of Coppernico Metals Inc. are listed on the Toronto Stock Exchange under the symbol “COPR”, trades on the OTCQB Venture Market under symbol “CPPMF” and is quoted over the counter by certain dealers in the Unofficial Market of the Frankfurt Stock Exchange under the symbol “9I3”. More information about Coppernico can be found on the Company’s profile on SEDAR+ (www.sedarplus.ca).

Cautionary Note

No regulatory organization has approved the contents hereof.

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend” and similar expressions and include, but are not limited to, statements with respect to: the Company’s preparations for Phase 2 drilling at the Sombrero Project; the timing and receipt of the final Start-of-Activities authorization; the commencement, execution and objectives of the planned drill program; the potential to expand known mineralization and make new discoveries; and participation in upcoming investor conferences. No certainty can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be heavily relied upon. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Readers should refer to the risks discussed in the Company’s 2025 Annual Information Form and other continuous disclosure filings with the Canadian Securities Administrators, available at www.sedarplus.ca. These factors are not, and should not be construed as being, exhaustive. Accordingly, readers should not place heavy reliance on forward-looking statements. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Any forward-looking information and the assumptions made with respect thereto speak only as of the date of this news release. The Company does not undertake any obligation to publicly update or revise any forward-looking information after the date of this news release to conform such information to actual results or to changes in the Company’s expectations except as otherwise required by applicable legislation.